SymBio Pharmaceuticals Limited
SYMQY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $6 | $10 | $8 |
| % Growth | -56.1% | -44.1% | 21.3% | – |
| Cost of Goods Sold | $1 | $1 | $2 | $2 |
| Gross Profit | $2 | $4 | $8 | $6 |
| % Margin | 76.4% | 78.9% | 75.9% | 70.3% |
| R&D Expenses | $0 | $3 | $3 | $2 |
| G&A Expenses | $0 | $0 | $0 | $1 |
| SG&A Expenses | $2 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $2 |
| Other Operating Expenses | $3 | $0 | -$0 | $0 |
| Operating Expenses | $6 | $5 | $6 | $5 |
| Operating Income | -$4 | -$1 | $2 | $1 |
| % Margin | -158.1% | -14.5% | 19.6% | 12.3% |
| Other Income/Exp. Net | $0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$4 | -$1 | $2 | $1 |
| Tax Expense | $0 | $1 | $1 | -$1 |
| Net Income | -$4 | -$2 | $1 | $2 |
| % Margin | -156.3% | -35.1% | 11.8% | 24.6% |
| EPS | -84.06 | -49.19 | 30.2 | 53.04 |
| % Growth | -70.9% | -262.9% | -43.1% | – |
| EPS Diluted | -84.06 | -49.19 | 29.77 | 52.32 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$1 | $2 | $1 |
| % Margin | -154.1% | -12.8% | 20.6% | 13.4% |